FDA Calls Novartis' Melanoma Combo Drug a Breakthrough Post author:Sam Post published:October 22, 2017 Post category:BioPharma The FDA based its decision on data from the COMBI-AD Phase III trial. Source: BioSpace You Might Also Like Ousted Arcturus Founder and CEO Claims He was Improperly Pushed Out by 4 Board Members February 6, 2018 Roche Gets in on Bay Area Allakos' $100M Funding Round December 12, 2017 A First: Novartis AG Drug May Prevent Heart Attacks and Cut Lung Cancer Risk Too August 27, 2017
Ousted Arcturus Founder and CEO Claims He was Improperly Pushed Out by 4 Board Members February 6, 2018
